R Paridaens
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Mauriac L, Castiglione-Gertsch M, Price K, Coates A, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group, Gelber R, Nogaret J, Keshaviah A, Debled M, Mouridsen H, Forbes J, Thürlimann B, Paridaens R, Monnier A, Láng I, Wardley A, International Breast Cancer Study Group. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 2007; 18:859-67.
May 1, 2007Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
May 1, 2007Ann Oncol 2007; 18:859-67
Mauriac L, Castiglione-Gertsch M, Price K N, Coates A S, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group, Gelber R D, Nogaret J-M, Keshaviah A, Debled M, Mouridsen H, Forbes J F, Thürlimann Beat, Paridaens R, Monnier A, Láng I, Wardley A, International Breast Cancer Study Group
Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
Perey L, Goldhirsch A, Köberle D, Clément P, Dietrich D, Fiche M, Wildiers H, Nolé F, Zaman K, Hawle H, Paridaens R, Thürlimann B. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007; 18:64-9.
Jan 1, 2007Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
Jan 1, 2007Ann Oncol 2007; 18:64-9
Perey L, Goldhirsch A, Köberle Dieter, Clément P, Dietrich D, Fiche M, Wildiers H, Nolé F, Zaman K, Hawle H, Paridaens R, Thürlimann Beat
Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group
Thürlimann B, Zurlo M, Lanzalone S, di Salle E, Murray R, Roché H, Bonneterre J, Serin D, Paridaens R, Piscitelli G. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. European journal of cancer (Oxford, England : 1990) 1997; 33:1767-73.
Oct 1, 1997Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group
Oct 1, 1997European journal of cancer (Oxford, England : 1990) 1997; 33:1767-73
Thürlimann Beat, Zurlo M G, Lanzalone S, di Salle E, Murray R, Roché H, Bonneterre J, Serin D, Paridaens R, Piscitelli G
Exemestane experience in breast cancer treatment
Lønning P, Paridaens R, Thürlimann B, Piscitelli G, di Salle E. Exemestane experience in breast cancer treatment. The Journal of steroid biochemistry and molecular biology 1997; 61:151-5.
Apr 1, 1997Exemestane experience in breast cancer treatment
Apr 1, 1997The Journal of steroid biochemistry and molecular biology 1997; 61:151-5
Lønning P E, Paridaens R, Thürlimann Beat, Piscitelli G, di Salle E